Recent advances in the management of psoriatic arthritis: practical considerations

Recent advances in the management of psoriatic arthritis 1 on both the patient quality of life and the efficacy / safety of PsA treatments. 4 PsA is a dynamic spectrum of disease that changes over time. 1 However, in the absence of biomarkers for personalized medicine, there is currently no way to predict the right treatment, for the right patient, at any one point in time. 5 This review aims to provide the reader with an overview of the similarities and differences between the major PsA treatment guidelines, including a detailed discussion of areas where guidelines and evidence are lacking, and that should be addressed urgently to further advance PsA care in the next decade and beyond.Conventional treatments for psoriatic arthritis Pharmacologic therapies should always be used in conjunction with lifestyle and nonpharmacologic interventions, such as smoking cessation, weight management, physiotherapy, hydrotherapy, podiatry, occupational therapy, and / or clinical psychology.Guidance on these interventions is covered elsewhere. 6Similarly, while there is a wide Introduction Psoriatic arthritis (PsA) is characterized by entheseal and synovial joint inflammation (axial and / or peripheral pattern) associated with a current, personal, or family history of skin or nail psoriasis and / or extramusculoskeletal manifestations (EMMs), including dactylitis, inflammatory bowel disease (IBD), and uveitis. 1 It is part of the wider family of spondyloarthropathies (SpA), alongside axial spondyloarthritis (axSpA), enteropathic arthritis, and reactive arthritis, all of which share overlapping clinical, biochemical, and genetic features. 2Several new biologic and targeted synthetic disease -modifying antirheumatic drugs (b/tsDMARDs) have been licensed for PsA in recent years 3 ; nevertheless, they are not universally efficacious, and can be associated with disabling adverse effects.On top of this, global population aging and increasing multimorbidity have the potential to impact on PsA in a particularly profound way, since PsA itself is a risk factor for cardiometabolic and psychosocial diseases, all of which, in turn, impact